查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血友病市场规模、份额和趋势分析报告：按类型、治疗类型、治疗方法、分销渠道、地区、细分市场趋势，2023-2030 年
市场调查报告书
商品编码
1321338

血友病市场规模、份额和趋势分析报告：按类型、治疗类型、治疗方法、分销渠道、地区、细分市场趋势，2023-2030 年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A), By Treatment Type (On-demand), By Therapy (Gene Therapy & Monoclonal Antibodies), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

血友病市场增长和趋势

Grand View Research, Inc.最新报告显示，预计2030年全球血友病市场规模将达到210.7亿美元，2023年至2030年年复合成长率为6.6%。

用于治疗血友病的基因疗法和单克隆抗体的批准以及多种此类候选药物的出现是市场增长的关键促进因素。此外，由于死亡率降低而延长血友病患者的预期寿命也是推动市场增长的关键因素。

控制血友病新疗法的开拓和推出正在推动市场增长。例如，2020年4月，FDA批准了基因工程产品Sevenfact【凝血因子VIIa（基因重组）-jncw】作为控制青少年（12岁及以上）和成人出血发作的治疗选择。此外，BioMarin 的 A 型血友病治疗药物 Roctavian 仅在欧洲获得批准，而 CSL 的 Hemgenix (etranacogene dezaparvovec-drib) 在美国和欧洲均获得批准。 Biomarin 的 Roctavian 在之前被拒绝后正在美国FDA 接受审查，PDUFA 日期定为 2023 年 6 月 30 日。

领先公司通过专注于新产品开发和战略联盟来扩大其地域影响力。例如，2022 年 4 月，诺和诺德 (Novo Nordisk) A/S 与加拿大血液服务公司 (Canadian Blood Services) 合作，加强其 Esperoct 和 Zonovate 的产品组合，这些产品作为 A 型治疗药物进行销售。此外，2023 年 2 月，赛诺菲的 Artuvio 获得 FDA 批准，这是一种治疗 A 型血友病的 VIII 因子替代疗法。

然而，在中国和印度等新兴国家，轻至中度症状的诊断延迟是一个主要障碍。市场面临的另一个主要挑战是，由于高成本和缺乏长期资料，获得基因治疗可能会出现问题。例如，Hemgenics 治疗（2022 年批准）每次治疗费用为 350 万美元，是世界上最昂贵的治疗方法。

血友病市场报告亮点

  • 在血友病市场中，由于A型血友病的高患病率以及多种治疗药物的存在，A型血友病占据最大份额。预计基因治疗的批准也将在预测期内实现最高的年复合成长率。
  • 从销售管道来看，2022年专科药品领域占据最大市场份额。
  • 从治疗方式来看，因子替代疗法在2022年占据血友病市场的最大份额。这是因为它是一种既用于预防又用于按需治疗的主要治疗方法。
  • 北美是 2022 年血友病市场创收最高的地区，这要归功于关键参与者的存在、法规支持、患者意识和有利的财务支持。

目录

第1章调查方法

第2章市场定义

第3章执行摘要

第4章血友病市场变量、趋势和范围

  • 血友病市场预测
    • 母公司市场预测
  • 绘製采用和增长预测
  • 市场促进因素分析
    • 新生儿数量增加
    • 有利的政府倡议
    • 加大研发力度和新产品开发
    • 更多地采用预防性治疗
  • 市场抑制因素分析
    • 采购治疗药物的成本高昂
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第5章血友病市场 - 按类型細項分析，2018-2030

  • 全球血友病市场：类型变异分析
  • 甲型血友病
  • 乙型血友病
  • 其他的

第6章血友病市场 – 細項分析，按治疗类型，2018-2030

  • 全球血友病市场：治疗类型变异分析
  • 预防
  • 一经请求
  • 康復

第7章血友病市场 - 細項分析（按治疗方法），2018-2030 年

  • 全球血友病市场：治疗波动分析
  • 因子替代疗法
  • 基因治疗和单克隆抗体
  • 去氨加压素和纤维蛋白密封剂

第8章血友病市场 - 按销售管道細項分析，2018-2030

  • 全球血友病市场：分销渠道变化分析
  • 医院药房
  • 专业药房

第9章血友病市场 - 区域細項分析，2018-2030

  • 血友病市场：区域展望
  • 北美
    • 北美血友病市场估计和预测，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲血友病市场估计和预测
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区血友病市场估计和预测
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 鲷鱼
  • 拉美
    • 拉丁美洲血友病市场估计和预测，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 中东和非洲血友病市场估计和预测，2018-2030 年
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第10章竞争形势

  • 企业分类
  • 参与企业概览
  • 财务绩效
  • 产品基准
  • 公司市场地位
  • 2022 年公司市场份额分析
  • 企业热图分析
  • 战略倡议
  • 公司简介
    • NOVO NORDISK A/S
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • F. HOFFMANN LA-ROCHE LTD.
    • BAYER AG
    • PFIZER, INC.
    • CSL BEHRING
    • BIOMARIN
    • OCTOPHARMA AG
    • SANOFI
    • SPARK THERAPEUTICS, INC.
Product Code: 978-1-68038-989-0

Hemophilia Market Growth & Trends

The global hemophilia market size is expected to reach USD 21.07 billion by 2030, expanding at a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights

  • The type A segment held the largest share of the hemophilia market owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy
  • Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2022, attributable to the specialized nature of the treatment required for the condition
  • By therapy factor replacement therapy held the largest share of the hemophilia market in 2022, as it is the major form of treatment used in both prophylaxis and on-demand treatment
  • North America was the largest revenue-generating region in the hemophilia market in 2022, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List Of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Hemophilia Market Variables, Trends, & Scope

  • 4.1 Hemophilia Market Lineage Outlook
    • 4.1.1 Parent Market Outlook
  • 4.2 Penetration And Growth Prospect Mapping
  • 4.3 Market Driver Analysis
    • 4.3.1 Increasing Population Of Newborns
    • 4.3.2 Favorable Government Initiatives
    • 4.3.3 Rising R&D And New Product Development
    • 4.3.4 Rising Adoption Of Prophylaxis Treatment
  • 4.4 Market Restraint Analysis
    • 4.4.1 High Cost Associated With Procuring Treatment
  • 4.5 Porter's Five Forces Analysis
  • 4.6 Pestle Analysis
  • 4.7 Pipeline Analysis

Chapter 5 Hemophilia Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 5.1 Global Hemophilia Market: Type Movement Analysis
  • 5.2. Hemophilia A5.2.1. Hemophilia A Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Hemophilia B
    • 5.3.1. Hemophilia B Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Hemophilia Market- Segment Analysis, By Treatment Type, 2018 - 2030 (USD Million)

  • 6.1 Global Hemophilia Market: Treatment Type Movement Analysis
  • 6.2. Prophylaxis
    • 6.2.1. Prophylaxis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3. On-Demand
    • 6.3.1. On-Demand Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Cure
    • 6.4.1. Cure Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Hemophilia Market - Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 7.1 Global Hemophilia Market: Therapy Movement Analysis
  • 7.2. Factor Replacement Therapy
    • 7.2.1. Factor Replacement Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1 Plasma Derived Factor Concentrates
      • 7.2.1.1.1 Plasma Derived Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.1.3 Factor Ix Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2 Recombinant Factor Concentrates
      • 7.2.1.2.1 Recombinant Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.3 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.2.1.2.4 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Gene Therapy & Monoclonal Antibodies
    • 7.3.1. Gene Therapy & Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Desmopressin & Fibrin Sealants
    • 7.4.1 Desmopressin & Fibrin Sealants Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Hemophilia Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 8.1 Global Hemophilia Market: Distribution Channel Movement Analysis
  • 8.2. Hospital Pharmacies
    • 8.2.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Specialty Pharmacies
    • 8.3.1. Specialty Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Hemophilia Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 9.1 Hemophilia Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 U.S. Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.2.2.3 Target Disease Prevalence
      • 9.2.2.4 Competitive Scenario
      • 9.2.2.5 Regulatory Framework
      • 9.2.2.6 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Canada Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.2.3.3 Target Disease Prevalence
      • 9.2.3.4 Competitive Scenario
      • 9.2.3.5 Regulatory Framework
      • 9.2.3.6 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 UK
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 UK Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.2.3 Target Disease Prevalence
      • 9.3.2.4 Competitive Scenario
      • 9.3.2.5 Regulatory Framework
      • 9.3.2.6 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Germany Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.3.3 Target Disease Prevalence
      • 9.3.3.4 Competitive Scenario
      • 9.3.3.5 Regulatory Framework
      • 9.3.3.6 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 France Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.4.3 Target Disease Prevalence
      • 9.3.4.4 Competitive Scenario
      • 9.3.4.5 Regulatory Framework
      • 9.3.4.6 Reimbursement Scenario
    • 9.3.5 Italy
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Italy Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.5.3 Target Disease Prevalence
      • 9.3.5.4 Competitive Scenario
      • 9.3.5.5 Regulatory Framework
      • 9.3.5.6 Reimbursement Scenario
    • 9.3.6 Spain
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Spain Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.6.3 Target Disease Prevalence
      • 9.3.6.4 Competitive Scenario
      • 9.3.6.5 Regulatory Framework
      • 9.3.6.6 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Denmark Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.7.3 Target Disease Prevalence
      • 9.3.7.4 Competitive Scenario
      • 9.3.7.5 Regulatory Framework
      • 9.3.7.6 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Sweden Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.8.3 Target Disease Prevalence
      • 9.3.8.4 Competitive Scenario
      • 9.3.8.5 Regulatory Framework
      • 9.3.8.6 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Norway Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.3.9.3 Target Disease Prevalence
      • 9.3.9.4 Competitive Scenario
      • 9.3.9.5 Regulatory Framework
      • 9.3.9.6 Reimbursement Scenario
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Japan Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.2.3 Target Disease Prevalence
      • 9.4.2.4 Competitive Scenario
      • 9.4.2.5 Regulatory Framework
      • 9.4.2.6 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 China Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.3.3 Target Disease Prevalence
      • 9.4.3.4 Competitive Scenario
      • 9.4.3.5 Regulatory Framework
      • 9.4.3.6 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 India Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.4.3 Target Disease Prevalence
      • 9.4.4.4 Competitive Scenario
      • 9.4.4.5 Regulatory Framework
      • 9.4.4.6 Reimbursement Scenario
    • 9.4.5 Australia
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Australia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.5.3 Target Disease Prevalence
      • 9.4.5.4 Competitive Scenario
      • 9.4.5.5 Regulatory Framework
      • 9.4.5.6 Reimbursement Scenario
    • 9.4.6 South Korea
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 South Korea Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.6.3 Target Disease Prevalence
      • 9.4.6.4 Competitive Scenario
      • 9.4.6.5 Regulatory Framework
      • 9.4.6.6 Reimbursement Scenario
    • 9.4.7 Thailand
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 Thailand Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.4.7.3 Target Disease Prevalence
      • 9.4.7.4 Competitive Scenario
      • 9.4.7.5 Regulatory Framework
      • 9.4.7.6 Reimbursement Scenario
  • 9.5 Latin America
    • 9.5.1 Latin America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Brazil Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.2.3 Target Disease Prevalence
      • 9.5.2.4 Competitive Scenario
      • 9.5.2.5 Regulatory Framework
      • 9.5.2.6 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Mexico Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.3.3 Target Disease Prevalence
      • 9.5.3.4 Competitive Scenario
      • 9.5.3.5 Regulatory Framework
      • 9.5.3.6 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Argentina Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.5.4.3 Target Disease Prevalence
      • 9.5.4.4 Competitive Scenario
      • 9.5.4.5 Regulatory Framework
      • 9.5.4.6 Reimbursement Scenario
  • 9.6 Middle East and Africa
    • 9.6.1 Middle East and Africa Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.1.1 Target Disease Prevalence
      • 9.6.1.2 Competitive Scenario
      • 9.6.1.3 Regulatory Framework
      • 9.6.1.4 Reimbursement Scenario
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 South Africa Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.2.3 Target Disease Prevalence
      • 9.6.2.4 Competitive Scenario
      • 9.6.2.5 Regulatory Framework
      • 9.6.2.6 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Saudi Arabia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.3.3 Target Disease Prevalence
      • 9.6.3.4 Competitive Scenario
      • 9.6.3.5 Regulatory Framework
      • 9.6.3.6 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 UAE Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.4.3 Target Disease Prevalence
      • 9.6.4.4 Competitive Scenario
      • 9.6.4.5 Regulatory Framework
      • 9.6.4.6 Reimbursement Scenario
    • 9.6.5 KUWAIT
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Kuwait Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
      • 9.6.5.3 Target Disease Prevalence
      • 9.6.5.4 Competitive Scenario
      • 9.6.5.5 Regulatory Framework
      • 9.6.5.6 Reimbursement Scenario

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Participant's Overview
  • 10.3 Financial Performance
  • 10.4 Product Benchmarking
  • 10.5 Company Market Positioning
  • 10.6 Company Market Share Analysis, 2022
  • 10.7 Company Heat Map Analysis
  • 10.8 Strategic Initiatives
  • 10.9 Company Profiles
    • 10.9.1 NOVO NORDISK A/S
    • 10.9.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 10.9.3 F. HOFFMANN LA-ROCHE LTD.
    • 10.9.4 BAYER AG
    • 10.9.5 PFIZER, INC.
    • 10.9.6 CSL BEHRING
    • 10.9.7 BIOMARIN
    • 10.9.8 OCTOPHARMA AG
    • 10.9.9 SANOFI
    • 10.9.10 SPARK THERAPEUTICS, INC.

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 19 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 20 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 21 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 22 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 23 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 24 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 26 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 27 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 28 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 29 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 30 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 31 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 32 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 33 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 34 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 35 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 36 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 37 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 38 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 39 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 40 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 41 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 42 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 43 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 44 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 45 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 46 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 47 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 48 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 50 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 51 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 52 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 53 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 54 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 55 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 56 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 57 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 59 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 60 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 61 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 62 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 63 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 64 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 65 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 66 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 67 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 68 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 69 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 70 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 71 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 72 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 73 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 74 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 75 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 76 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 77 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 78 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 79 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 80 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 81 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 82 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 83 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 84 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 85 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 86 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 87 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 88 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 89 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 90 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
  • TABLE 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 116 KUWAIT Hemophilia Market, By Type, 2018 - 2030 (USD Million)
  • TABLE 117 KUWAIT Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
  • TABLE 118 KUWAIT Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
  • TABLE 119 KUWAIT Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global hemophilia market- Key market driver analysis
  • FIG. 7 Global hemophilia market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global hemophilia market - Porter's analysis
  • FIG. 10 Global hemophilia market - PESTEL analysis
  • FIG. 11 Global hemophilia market type outlook key takeaways
  • FIG. 12 Global hemophilia market: Type movement analysis
  • FIG. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
  • FIG. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
  • FIG. 15 Others market estimates, 2018 - 2030 (USD Million)
  • FIG. 16 Global hemophilia market treatment outlook key takeaways
  • FIG. 17 Global hemophilia market: Treatment Type movement analysis
  • FIG. 18 On-demand market estimates, 2018 - 2030 (USD Million)
  • FIG. 19 Cure market estimates, 2018 - 2030 (USD Million)
  • FIG. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
  • FIG. 21 Global hemophilia market therapy outlook key takeaways
  • FIG. 22 Global hemophilia market: Therapy movement analysis
  • FIG. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
  • FIG. 24 Desmopressin & Fibrin Sealants market estimates, 2018 - 2030 (USD Million)
  • FIG. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
  • FIG. 26 Regional marketplace: Key takeaways
  • FIG. 27 Global hemophilia market: Regional movement analysis
  • FIG. 28 North America hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 32 UK hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 34 France hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 42 China hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 43 India hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
  • FIG. 54 UAE market, 2018 - 2030 (USD Million)
  • FIG. 55 Kuwait market, 2018 - 2030 (USD Million)
  • FIG. 56 Strategy framework